Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

Going bald sucks. Finasteride does not. Millions of men use it every year to help them keep the hair they have and maybe even ...

Rosuvastatin comes as an oral tablet and belongs to a group of ... In some cases, they may not be available in every strength or form as the brand-name drug. This drug may be used as part of ...

It comes as an oral tablet and an oral liquid solution ... Sometimes, they may not be available in all the same strengths or forms as the brand-name drug. »Learn more about how generics compare ...

Items that will be accepted are tablets, capsules, patches, and other solid forms of prescription drugs ... Ellis County Drug Enforcement Unit, at 785-621-1668.

What happens when prescription drugs cost so much, there isn't enough room on web forms to fit the whole price? Medicare found a work-around. More from STAT: Become a ...

Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage strengths ... “The approval of Livmarli in tablet form provides a meaningful additional treatment option for patients with ...

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and ...

The first targeted treatment for the most common form of bladder ... in England. The drug, also known as Balversa and made by Johnson & Johnson, is taken as a once-a-day tablet and works by ...

School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States Wallace Coulter Department of Biomedical Engineering at Georgia Tech and Emory ...